Physician profile
Michael C Bertram
NPI 1992882864
$14,606.35
in general payments reported to CMS, 2019-2025
43 companies · $414 in 2025
The $414 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,961 · 2020: $830 · 2021: $1,374 · 2022: $1,893 · 2023: $3,567 · 2024: $3,568 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,548.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,032.56 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $2,019.02 | 2019-2025 | Evenity, Repatha, Otezla |
| Abbvie INC. | $1,346.32 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Glaxosmithkline, LLC. | $1,085.04 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $744.82 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $655.36 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $614.07 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $534.38 | 2019-2024 | |
| Abbott Laboratories | $513.14 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $364.21 | 2019-2024 | Ofev, Jardiance |
| Astellas Pharma US INC | $324.14 | 2019-2024 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $262.95 | 2019-2025 | Xifaxan |
| Amarin Pharma, INC. | $244.09 | 2019-2020 | |
| Grifols USA, LLC | $232.96 | 2022-2023 | Gamunex-C |
| Sumitomo Pharma America, INC. | $213.93 | 2023-2024 | Gemtesa |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bertram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.